Contract 75N93020C00055

Biocryst Pharmaceuticals Inc · Department Of Health And Human Services · August 19, 2024

Cost Plus Fixed FeeFull & Open CompetitionNAICS 541715

Biocryst Pharmaceuticals Inc was awarded a federal contract by Department Of Health And Human Services (National Institutes Of Health) on August 19, 2024 for $2.61 million (current value) of work in research and development in the physical, engineering, and life sciences (except nanotechnology and biotechnology). Performance is in Durham, NC. It was awarded under full and open competition. The contract has been modified 1 time since the base award It uses cost-plus contract pricing. The most recent modification was on August 19, 2024. If all options are exercised, the contract could reach $40.20 million.

Current value
$2.61M
Potential value
$40.20M
if all options exercised
Modifications
1
Latest August 19, 2024

Contract details

PIID
75N93020C00055
Award type
Definitive Contract
Pricing
Cost Plus Fixed Fee
Set-aside
No Set Aside Used.
Competition
Full And Open Competition
NAICS
541715 · Research And Development In The Physical, Engineering, And Life Sciences (Except Nanotechnology And Biotechnology)
Product / service
General Science And Technology R&D Services; General Science And Technology; Applied Research
Place of performance
Durham, NC
First action
August 19, 2024
Latest action
August 19, 2024

Description

EXTEND PERIOD OF PERFORMANCE FOR THE BASE TILL SEPTEMBER 30, 2022. (NOTE: THE MODIFICATION P00003 IS MODIFICATION P00002 IN THE NBS SYSTEM, MODIFICATION P00004 IS MODIFICATION P00003 IN THE NBS SYSTEM AND THESE ARE CLARIFICATIONS FOR AUDIT PURPOSES

Modification timeline

  • August 19, 2024
    Mod P00004 · Other Administrative Action
    $2.61M
  • August 19, 2024
    Mod P00005 · Close Out
    TO DE-OBLIGATE REMAINING FUNDS AND ADMINISTRATIVELY CLOSE THE CONTRACT.
    $2.61M

Similar contracts

RecipientAgencyDateObligated
The Emmes Company, LlcDepartment Of Health And Human ServicesApril 1, 2026$771.5K
Leidos Biomedical Research IncDepartment Of Health And Human ServicesApril 1, 2026$327.13M
Leidos Biomedical Research IncDepartment Of Health And Human ServicesApril 1, 2026$8.00M
Lovelace Biomedical Research InstituteDepartment Of Health And Human ServicesApril 1, 2026$680.2K
Leidos Biomedical Research IncDepartment Of Health And Human ServicesApril 1, 2026$9.22M
The Brain Donor Project, IncDepartment Of Health And Human ServicesApril 1, 2026$1.27M

Top contractors in NAICS 541715

Lifetime obligated dollars across all federal contracts in this NAICS code.

#ContractorContractsObligated
1Fluor Marine Propulsion, Llc2$2.75B
2California Institute Of Technology240$979.40M
3The Johns Hopkins University Applied Physics Laboratory Llc204$482.74M
4Lockheed Martin Corporation4$461.91M
5Lockheed Martin Corp9$317.27M
6The Aerospace Corporation85$308.18M
7Fermi Forward Discovery Group, Llc1$289.92M
8Lockheed Martin Corp7$285.45M
9Amentum Technology, Inc.4$253.24M
10The Mitre Corporation50$222.51M

Track this on BesaGov

Get a free weekly email when this changes — new awards, new sub-awards, new opportunities. No login required.

✓ You’re on the list. We’ll never spam you.

Helpful guides

Continue learning

See all guides →
More on BesaGov

Keep researching

Track this contract, set alerts on similar opportunities, and build proposal pipelines on BesaGov.
Sign up free

Frequently asked questions

What is contract 75N93020C00055?

Contract 75N93020C00055 is a federal contract awarded to Biocryst Pharmaceuticals Inc by Department Of Health And Human Services on August 19, 2024 for $2.61 million of work classified under RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY). It has been modified 1 time since the base award.

Who won contract 75N93020C00055?

Biocryst Pharmaceuticals Inc won contract 75N93020C00055 from Department Of Health And Human Services.

How much is contract 75N93020C00055 worth?

Contract 75N93020C00055 has obligated $0 to date but carries a potential ceiling of $40.20 million if fully funded and all options are exercised.